by dtrubin | Dec 3, 2019 | QoL, Rubin's Reflections
IBD, perhaps more than other chronic illnesses, can have a definite impact on a patient’s career choices and school performance. Therefore, I have definitely seen patients make decisions that are affected by their IBD. However, more often, I’ve seen patients overcome...
by dtrubin | Nov 5, 2019 | In the Press, Presentations, UC
Dr. Rubin discusses his presentation at ACG 2019 in San Antonio on identifying and managing patients with high-risk ulcerative colitis with Healio Gastroenterology. “The importance of knowing who is high risk has to do with your choices of treatment and your...
by dtrubin | Sep 18, 2019 | In the Press
‘In this installment of “Expert Picks,” David Rubin, MD, the Joseph B. Kirsner Professor of Medicine; the chief of the Section of Gastroenterology, Hepatology, and Nutrition; and a co-director of the Digestive Diseases Center at the University of Chicago...
by dtrubin | Aug 14, 2019 | In the Press, monitoring, therapies
Dr. Mark Silverberg, Dr. David T Rubin, Dr. Laura Targownik, and Dr. Charabaty excitingly discuss why IBD specialists are divided on the topic of therapeutic drug monitoring (TDM). “If the drug is going to work but isn’t present in the body, it doesn’t do its job,”...
by dtrubin | Jun 27, 2019 | histology, In the Press, normalization, UC
“These patients require ongoing monitoring and follow-up,” the study’s first author, Amanda M. Israel, MD, also of the University of Chicago Medicine, told MedPage Today. Our graduating Advanced IBD Fellow, Amanda Israel, was published her findings...
